Shares of Biohaven Pharmaceutical BHVN decreased 0.1% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were up 5.61% year over year to ($2.69), which beat the estimate of ($2.97).
Revenue of $35,114,000 up by 0.00% year over year, which beat the estimate of $28,230,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Biohaven Pharmaceutical hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Mar 01, 2021
Time: 08:30 AM
ET Webcast URL: https://event.webcasts.com/starthere.jsp?ei=1425489&tp_key=b366aed301
Technicals
Company's 52-week high was at $100.77
52-week low: $26.56
Price action over last quarter: down 1.69%
Company Description
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.